MGMT and glioblastoma: Both kits (PyroMark Q24 CpG MGMT and Therascreen MGMT PyroKit) have demonstrated their capability to stratify patients with GBM according to its prognostic after measuring MGMT promoter methylation (Johannessen et al., 2018).